Back to results
US 7,547,711 B2Granted
Heterocyclic inhibitors of kinases
AssigneeBristol-Myers Squibb Company
InventorsRobert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Claims2
A compound of formula I
- wherein
- A is aryl or substituted aryl;
- B is heteroaryl or substituted heteroaryl;
- X is R1CR2;
- Y is —NH—;
- D is S;
- R1 and B2 are hydrogen;
- and
- enantiomers, diastereomers, and pharmaceutically acceptable salts, and prodrugs thereof.
6 more elements
Dependencies are inferred from the claim text.